The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Advances in Biologics Development and Delivery” on Thursday, March 28, 2019 at the University of California, San Francisco (UCSF), Mission Bay Campus, San Francisco.
SOMERSET, N.J. – March 19, 2019 — The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Advances in Biologics Development and Delivery” on Thursday, March 28, 2019 at the University of California, San Francisco (UCSF), Mission Bay Campus, San Francisco.
The symposium will be chaired by Cornell Stamoran, Ph.D., Co-Chair of the Catalent Applied Drug Delivery Institute, and will bring together world-leading experts on biological drug development and delivery from across the industry, including Wesley Jackson, Ph.D., CEO and Co-Founder, Valitor, Inc.; and from academia, including David Schaffer, Ph.D., Professor, University of California, Berkeley and Francis Szoka, Ph.D., Professor, UCSF.
The event will include presentations on leading-edge biological research and will cover key industry topics, from cell line development through to commercialization. The symposium will close with a networking reception.
Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies to improve patient outcomes.
Registration and full details of the agenda can be found here.
+44 (0)7580 041073
+44 (0)161 728 5880
About the Catalent Applied Drug Delivery Institute
The Catalent Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.